Microcap Ledger

Tickers · $MGRX

Mangoceuticals, Inc. $MGRX

By Microcap Ledger desk · CIK 0001938046

Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange
Nasdaq Capital Market
Sector
Services-Misc Health & Allied Services, NEC
Headquarters
Dallas, TX
Fiscal year end
December 31
Shares outstanding
21,567,422 [10-Q 2026-08-13]
as of 2026-08-13

Sources: [10-K 2026-04-01]

What the company doesAI summary of filing

Mangoceuticals, Inc. sells compounded pharmaceutical products through its website via telemedicine consultations. The company's products are compounded by a related-party pharmacy, Epiq Scripts, and distributed directly to customers. The company is currently revenue-generating, selling compounded products for erectile dysfunction (Mango ED), hair loss (Mango GROW), hormone management (Mango MOJO), and weight management (Mango SLIM). Products are prescribed by physicians through the company's telemedicine platform and fulfillment is handled exclusively by Epiq Scripts. [10-K 2026-04-01]

Segments: Mango ED, Mango GROW, Mango MOJO, Mango SLIM

Financial health

From XBRL company facts (USD)
PeriodRevenueNet incomeOperating cash flowCashFiling
6 months to Jun 2026$136.6K−$4.72M −$1.57M$228.7K[10-Q 2026-08-13]
FY ended Dec 2025$456.0K−$20.64M −$5.85M$1.49M[10-K 2026-04-01]
FY ended Dec 2024$615.9K−$8.71M −$4.86M$58.7K[10-K 2026-04-01]
Quarterly cash burn
−$785.9K
Cash runway Estimate
~0.9 months

Estimate: cash at the end of the period (6 months to Jun 2026) divided by the average monthly operating cash outflow over that period. Ignores any cash raised or spent since, and any financing.

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
DateShares outstandingFiling
2024-11-142,486,512[10-Q 2024-11-14]
2025-03-205,168,796[10-K 2025-03-20]
2025-05-1511,034,023[10-Q 2025-05-15]
2025-08-1410,535,791[10-Q/A 2025-11-14]
2025-11-1313,906,570[10-Q 2025-11-14]
2026-03-3116,967,420[10-K 2026-04-01]
2026-05-1517,167,422[10-Q 2026-05-19]
2026-08-1321,567,422[10-Q 2026-08-13]
Shelf registration
S-1 filed 2026-01-13; declared effective 2026-01-28 [S-1 2026-01-13]

Listing status

Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-02-06. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.

DateEventDetailsDeadlineFiling
2026-02-068-K Item 3.01Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing—[8-K 2026-02-06]

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
DateInsiderTypeSharesPriceFiling
2026-08-11Cohen Jacob D.other2,000,000—[4 2026-10-06]
2026-08-11Cohen Jacob D.other2,000,000—[4 2026-10-06]
2026-07-28Cohen Jacob D.grant2,000,000—[4 2026-10-06]
2026-07-28Johnston Eugene Mgrant100,000—[4 2026-10-06]
2026-07-28Hamilton Alex P.grant100,000—[4 2026-10-06]
2025-12-15Johnston Eugene Msell3,333$1.17[4 2025-12-17]
2025-12-09Johnston Eugene Msell5,000$1.20[4 2025-12-11]
2025-12-05Johnston Eugene Msell10,000$1.13[4 2025-12-09]
2025-09-30Cohen Jacob D.other500,000—[4 2026-10-06]
2025-09-30Cohen Jacob D.other500,000—[4 2026-10-06]
2025-09-09Cohen Jacob D.grant500,000—[4 2026-03-20]
2025-06-05Cohen Jacob D.other200,000—[4 2026-03-20]

Catalysts and calendar

Facts as of . Small caps move fast; check the latest filings.